RNA-based Therapeutics and Vaccines

Global Market Trajectory & Analytics

MCP14477

EXECUTIVE ENGAGEMENTS

POOL

431
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

86
Interactions with Platform & by Email

PARTICIPANTS

17
Unique # Participated

VALIDATIONS

7
Responses Validated*

COMPANIES

41
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

76

PAGES

147

EDITION

6

PRICE

USD 4950

CODE

MCP14477


COMPETITIVE METRICS

COMPANY

D S N T

% *

Accelero Bioanalytics GmbH

Login Required

Alnylam Pharmaceuticals, Inc.

Login Required

Applied Molecular Transport

Login Required

Arbutus Biopharma Corporation

Login Required

Arcturus Therapeutics, Inc.

Login Required

Arrowhead Pharmaceuticals, Inc.

Login Required

Axolabs

Login Required

BioNTech AG

Login Required

Biorchestra Company Limited

Login Required

CureVac AG

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 41 COMPETITORS

Login to access data silos

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for RNA-based Therapeutics and Vaccines estimated at US$14.7 Million in the year 2020, is projected to reach a revised size of US$499 Million by 2027, growing at aCAGR of 65.5% over the period 2020-2027. RNA-based Therapeutics, one of the segments analyzed in the report, is projected to record 68.1% CAGR and reach US$372.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the RNA-based Vaccines segment is readjusted to a revised 59.2% CAGR for the next 7-year period.
The RNA-based Therapeutics and Vaccines market in the U.S. is estimated at US$4.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$76.6 Million by the year 2027 trailing a CAGR of 62% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 59.2% and 55.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 43.7% CAGR.

SELECT PLAYERS

Alnylam Pharmaceuticals, Inc.; Arbutus Biopharma Corporation; Arrowhead Pharmaceuticals, Inc.; BioNTech AG; CureVac AG; Dicerna Pharmaceuticals, Inc.; Marina Biotech, Inc.; miRagen Therapeutics, Inc.; Moderna, Inc.; Quark Pharmaceuticals, Inc.; Regulus Therapeutics, Inc.; Sylentis S.A.

SEGMENTS

» Indication (Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases, Other Indications) » Product Type (RNA-based Therapeutics, RNA-based Vaccines)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for RNA-based Therapeutics and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for RNA-based Therapeutics and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
World Current & Future Analysis for RNA-based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for RNA-based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for RNA-based Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for RNA-based Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Genetic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Genetic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
USA Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
CANADA
Canada Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Canada Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
JAPAN
Japan Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Japan Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
CHINA
China Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
China Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
EUROPE
Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
FRANCE
France Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
France Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
GERMANY
Germany Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Germany Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
ITALY
Italy Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Italy Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
UK Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
Rest of World Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
Total Companies Profiled: 41

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com